Supplementary

Sensitivity Analyses Methods
We tested the definition of ART use by considering treatment interruptions, classifying any person-month after ART initiation in which an individual did not appear to have been prescribed ART as a treatment interruption. As this measure relies on treatment stop dates recorded in patient health records, this approach will likely capture only scheduled treatment interruptions, as opposed to interruptions due non-adherence, for example, of which the care-giving clinician may not be aware. We also tested the definition of LTCFU by changing the number of cumulative months required to be NIC to either six or twelve. Finally, we re-estimated the ten-year longitudinal continuum restricting to individuals who had at least two visit dates in the UK CHIC cohort. This is more consistent with previous analyses of the REACH algorithm 1,2 and excludes attenders who have only one record of contact with a clinic, who would become almost immediately LTCFU and are less likely to have complete information available in the UK CHIC Study on demographic or clinical characteristics and outcomes.
Results
Scheduled treatment interruption accounted for a relatively low percentage of person-months over ten years (4·7%; n=72,200)[ Supplementary Figure 1] . Discounting those undergoing a treatment interruption, we observed that of all person-months on ART over ten years (n=738,857), 80·1% (n=592,635) were spent virologically suppressed (as opposed to 74.5% in the main analysis).
Using six or twelve months NIC to define LTCFU made little difference to the longitudinal continuum. Using a six month definition we saw that 20·9% (n=321,153) of all person-months over ten years were classified as true LTC and 6·0% (n=92,729) as transfer of care. Using a twelve month definition we observed that 17·6% (n=270,470) and 5·3% (n=81,571) were classified as true LTC and transfer of care. Restricting to 11,272 (88·0%) individuals who had at least two separate visits in the UK CHIC study, rates of true LTC were lower than observed in the main analysis (14.9% (n=201,282)), and a larger proportion of person-months were spent with viral suppression (44·9% (n=606,647) ). ART-/EIC/CD4 >350=ART-Naïve, Engaged in care, CD4 >350 cells per µL (n=130114) ; ART-/EIC/CD4 <350=ART-Naïve, Engaged in care, CD4 <350 cells per µL (n=82102); ART-/NIC=ART-Naïve, Not in care (n=74917); ART+/EIC/VL>200=ART-experienced, Engaged in care, viral load >200 copies per mL (n=84100); ART+/EIC/VL ≤200=ART-experienced, Engaged in care, viral load ≤200 copies per mL (n=567036); ART+/NIC/VL ≤200=ART-experienced, Not in care, viral load ≤200 copies per mL (n=25599); ART+/NIC/VL>200=ART-experienced, Not in care, viral load >200 copies per mL (n=62122); Treatment Interruption (n=72200); True LTC=Lost to cohort follow-up (LTCFU) with no record of attendance in the HIV/AIDS Reporting System (HARS) (n=293048); Transfer=LTCFU with record of attendance in HARS (n=86771). 
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